Autres langues Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 20:28:37 17/06/2026			Varia. 5j.	Varia. 1 janv.
458,96 ^USD	+1,28%		+5,22%	+1,12%

11/06	Vertex : les données cliniques de phase avancée du Casgevy confirment l'absence de crises et de transfusions chez les enfants atteints de troubles sanguins	MT
11/06	Vertex Pharmaceuticals Incorporated présente de nouvelles données sur le Casgevy et annonce de nouveaux dépôts de dossiers réglementaires à l'échelle mondiale	CI

Autres langues

11/06	Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
11/06	Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions
09/06	Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing
09/06	Münchner Biotechfirma erhält Zulassung für neuartiges Cannabis-Schmerzmittel
05/06	Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
05/06	Compañías que se deben tener muy en cuenta por técnico este viernes
05/06	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca
05/06	Valores destacados al cierre del mercado norteamericano
04/06	Otsuka says kidney disease drug preserves function in late-stage study
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
02/06	Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing
01/06	Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
01/06	Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
21/05	Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
21/05	Vertex Says Health Canada Accepts Suzetrigine Application for Review
21/05	Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada
19/05	Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing
13/05	Declaration of Voting Results by Vertex Pharmaceuticals Incorporated
13/05	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
13/05	Valores destacados al cierre del mercado norteamericano
11/05	Vertex to Participate in Upcoming May Investor Conferences
07/05	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany